.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB07_InterferonBeta1a.InterferonBeta1a_1

Information

Interferon beta-1a is a recombinant form of human interferon beta, used primarily in the treatment of relapsing forms of multiple sclerosis (MS). It is approved by regulatory agencies such as the FDA and EMA for MS to reduce frequency of relapses and slow progression of physical disability.

Pharmacokinetics

Pharmacokinetics reported for adult MS patients after subcutaneous administration of 44 micrograms three times a week.

References

1. Hu, X, et al., & Werneburg, B (2016). COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. British journal of clinical pharmacology 82(2) 380–388. DOI:10.1111/bcp.12968 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27060836

2. Hoy, SM (2015). Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS drugs 29(2) 171–179. DOI:10.1007/s40263-015-0227-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25666445

3. Coyle, PK, et al., & Castrillo-Viguera, C (2018). Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week. Multiple sclerosis and related disorders 22 134–138. DOI:10.1016/j.msard.2018.02.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29679749

Revisions

• 06/2025 initial generated model